Milestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research report sent to investors on Thursday, MarketBeat.com reports. The brokerage issued an overweight rating and a $4.00 price target on the stock.

Separately, HC Wainwright raised shares of Milestone Pharmaceuticals to a “buy” rating and set a $5.00 price objective for the company in a report on Thursday, June 5th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Milestone Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $4.50.

Milestone Pharmaceuticals Stock Up 11.7%

Shares of MIST opened at $1.91 on Thursday. The business’s 50 day moving average is $1.70 and its 200 day moving average is $1.55. The company has a market capitalization of $162.33 million, a PE ratio of -2.27 and a beta of 0.60. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $2.75. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 4.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Research analysts expect that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Propel Bio Management LLC purchased a new position in shares of Milestone Pharmaceuticals in the 1st quarter worth approximately $1,161,000. Simplify Asset Management Inc. boosted its holdings in shares of Milestone Pharmaceuticals by 16.5% in the 2nd quarter. Simplify Asset Management Inc. now owns 990,000 shares of the company’s stock worth $1,921,000 after purchasing an additional 140,000 shares during the period. Toronto Dominion Bank purchased a new position in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $1,770,000. XTX Topco Ltd boosted its holdings in shares of Milestone Pharmaceuticals by 209.5% in the 2nd quarter. XTX Topco Ltd now owns 160,963 shares of the company’s stock worth $312,000 after purchasing an additional 108,959 shares during the period. Finally, Valeo Financial Advisors LLC boosted its holdings in shares of Milestone Pharmaceuticals by 553.5% in the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after purchasing an additional 110,699 shares during the period. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.